

ASX ANNOUNCEMENT

19 October 2009

Resignation of Director

Cytopia announced today that Mr. Roderick Lyle, a non executive director of the Company will retire from the Cytopia Board with immediate effect, due to recent ill health.

Cytopia's chairman, Mr. Bob Watson said "Since his appointment in 2005, Mr Lyle has made an excellent contribution to the Cytopia board, both as a director and as Chair of the Audit and Risk Committee. We are sorry to have lost Rod's services and wish him a speedy recovery."

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Australia and the USA and specialises in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The lead program for the company is CYT997, a vascular disrupting agent for the treatment of various cancers, and currently being trialled in Phase II clinical studies. Cytopia also is building on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter a Phase I/II clinical study in 2009.

On 6 October 2009, Cytopia announced a proposed merger with Toronto, Canada based YM BioSciences Inc. Details can be found at www.cytopia.com.au. It is expected that a Scheme Booklet, further explaining the basis for the merger, will be provided to Cytopia shareholders in November 2009.

For more information please contact:

Mr Ashley Arnott
Company Secretary
T: +61 3 9208 4236
E: ashley.arnott@cytopia.com.au